ERBB2 and breast cancer: Among the many BC subtypes, estrogen receptor-positive (ER+) breast cancer accounts for 60–70% of cases, HER2 overexpression accounts for 10–15%, and triple negative breast cancer (TNBC) accounts for 15–20% of cases [2].